Current Duke Appointments & Affiliations
Associate Professor of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2011 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.
Journal article Prostate Cancer Prostatic Dis · August 5, 2026 BACKGROUND: Identifying clinical and genomic predictors of response to androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) for metastatic androgen pathway modulator sensitive (APMS) prostate cancer is essential for improving ... Full text Link to item CiteClinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.
Journal article Res Sq · July 1, 2026 BACKGROUND: Survival outcomes following sipuleucel-T in men with metastatic androgen pathway modulator resistant prostate cancer (mAPMR) are variable. Genomic alterations influencing immune response and tumor proliferation may explain outcome heterogeneity ... Full text Link to item CiteReal-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.
Conference Journal of Clinical Oncology · March 1, 2026 Lack of standardized reporting and collection of patient-reported outcomes (PROs) limits cross-trial comparisons of first-line IO-based regimens for mRCC. Prospectively collected real world data may fill this important knowledge gap. Pts with stable/improv ... Full text CiteRecent Grants
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (PEAK-1)
Clinical TrialPrincipal Investigator · Awarded by Arcus Biosciences · 2026 - 2031Prostate Cancer Research Program Clinical Consortium Award
ResearchCollaborating Investigator · Awarded by Department of Defense · 2026 - 2030A Randomized Phase 2 Trial of Nivolumab, Relatlimab plus Ipilimumab vs. Nivolumab plus Ipilimumab in first-line advanced renal cell carcinoma (RCC)
Clinical TrialPrincipal Investigator · Awarded by The University of Texas MD Anderson Cancer Center · 2025 - 2030View All Grants
Education
Tulane University ·
2004
M.D.